- Home
- VRCA
as 11-08-2024 9:38am EST
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WEST CHESTER |
| Market Cap: | 363.1M | IPO Year: | 2018 |
| Target Price: | $7.33 | AVG Volume (30 days): | 646.5K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.70 - $11.41 | Next Earning Date: | 11-04-2024 |
| Revenue: | $9,210,000 | Revenue Growth: | 187.45% |
| Revenue Growth (this year): | 291.12% | Revenue Growth (next year): | 104.31% |
Stock Insider Trading Activity of Verrica Pharmaceuticals Inc. (VRCA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hayes Christopher G. | VRCA | CHIEF LEGAL OFFICER | Aug 26 '24 | Sell | $2.56 | 35,713 | $93,090.58 | 105,773 | |
| Goldenberg Gary | VRCA | Chief Medical Officer | Aug 26 '24 | Sell | $2.56 | 13,489 | $35,160.54 | 97,862 | |
| Kohler Terry | VRCA | CHIEF FINANCIAL OFFICER | Aug 26 '24 | Sell | $2.56 | 29,719 | $77,472.74 | 52,596 | |
| Bonaccorso Joe | VRCA | CHIEF COMMERCIAL OFFICER | Aug 26 '24 | Sell | $2.56 | 33,702 | $87,848.72 | 73,114 | |
| White Ted | VRCA | PRESIDENT AND CEO | Aug 26 '24 | Sell | $2.56 | 34,000 | $88,635.80 | 224,988 |
Latest Verrica Pharmaceuticals Inc. News
VRCA Breaking Stock News: Dive into VRCA Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
GlobeNewswire
15 days ago
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
GuruFocus.com
a month ago
Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ...
MT Newswires
a month ago
RBC Lowers Price Target on Verrica Pharmaceuticals to $11 From $13, Keeps Outperform, Speculative Risk
MT Newswires
a month ago
Sector Update: Health Care Stocks Softer Wednesday Afternoon
MT Newswires
a month ago
Verrica Pharmaceuticals to Restructure Sales, Operating Teams; Cut Sales Territories
GlobeNewswire
a month ago
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
Insider Monkey
a month ago
Verrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now
Compare VRCA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRCA Verrica Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.